Compass Pathways shares surge 10.18% intraday after FDA accepts COMP360 IND for PTSD, enabling late-stage trial initiation.

Compass Pathways surged 10.18% intraday after announcing the FDA accepted its IND application for COMP360 in PTSD, enabling a Phase 2b/3 trial. The move followed the company’s disclosure of late-stage clinical plans for PTSD and progress toward commercial readiness for TRD, including a webinar with key opinion leaders and industry experts on January 7, 2026. The FDA acceptance validates Compass’s pipeline expansion into PTSD, a high-unmet-need market with only two approved therapies, while the webinar underscored strategic momentum ahead of potential regulatory milestones. Additionally, the company’s amended $150 million term loan facility with Hercules Capital, extending repayment terms and enhancing liquidity, provided further confidence in its ability to fund trials and commercialization efforts. The stock’s sharp intraday rise reflects investor optimism over regulatory progress and the therapeutic potential of COMP360 in addressing PTSD and TRD.